Technical Analysis for CBAY - CymaBay Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 11.93 -7.66% -0.99
CBAY closed down 7.66 percent on Friday, March 22, 2019, on 1.64 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical CBAY trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Down 4 Days in a Row Weakness 0.00%
Mar 22 Gapped Down Weakness 0.00%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -7.66%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.66%
Mar 21 Down 3 Days in a Row Weakness -7.66%
Mar 20 1,2,3 Pullback Bullish Bullish Swing Setup -7.88%

Older signals for CBAY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Medicine Chemistry Disorders Health Care Therapeutic Products Regulus Therapeutics Metabolic Diseases Ii Diabetes Gout
Is CBAY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.0
52 Week Low 6.31
Average Volume 755,574
200-Day Moving Average 11.041
50-Day Moving Average 10.6152
20-Day Moving Average 12.6415
10-Day Moving Average 12.971
Average True Range 0.7082
ADX 38.07
+DI 23.6248
-DI 19.8003
Chandelier Exit (Long, 3 ATRs ) 11.8754
Chandelier Exit (Short, 3 ATRs ) 11.9346
Upper Bollinger Band 14.1098
Lower Bollinger Band 11.1732
Percent B (%b) 0.26
BandWidth 23.229838
MACD Line 0.6488
MACD Signal Line 0.8331
MACD Histogram -0.1843
Fundamentals Value
Market Cap 522.01 Million
Num Shares 43.8 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -11.15
Price-to-Sales 82.44
Price-to-Book 122.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.30
Resistance 3 (R3) 13.44 13.14 13.07
Resistance 2 (R2) 13.14 12.79 13.06 12.99
Resistance 1 (R1) 12.53 12.57 12.38 12.39 12.92
Pivot Point 12.23 12.23 12.15 12.15 12.23
Support 1 (S1) 11.62 11.88 11.47 11.48 10.94
Support 2 (S2) 11.32 11.66 11.24 10.87
Support 3 (S3) 10.71 11.32 10.79
Support 4 (S4) 10.57